Analyst Downgrades AstraZeneca Stock Due to Vaccine Side Effect Concerns

Analyst Downgrades AstraZeneca Stock Due to Vaccine Side Effect Concerns
Cory Renauer, The Motley Fool
·2 min read

The odds of experiencing a fatal blood clot following inoculation with AstraZeneca's COVID-19 vaccine are less than one in a million, but that was enough to spook Argus Research.